Citeline

NEW YORK, August 11, 2011 - Alzheimer's Association Analysis of APOE-e4 on amyloid deposits shows abnormal levels can be detected at least 10-years and possibly 20-years prior to onset Citeline, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials recently reviewed the findings from the 14th International Conference on Alzheimer's Disease (ICAD 2011/AAIC 2011) July 16-21, 2011, noting that while pharma continues to develop beta amyloid targeting drugs, amyloid targets are moving ahead in terms of biomarkers and early warning for risk of Alzheimer's.

NEW YORK, June 2, 2011 - - Trials targeting non-small cell lung cancer, breast cancer and multiple hematological cancers are amongst the most active, while Roche and Novartis had the most oncology trial starts of any company Citeline, the world's leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the oncology therapeutic area to uncover trends and patterns in drug development.